JP5150891B2 - シモン芋エキスとシモン芋由来のスフィンゴ糖脂質、及びその製造方法 - Google Patents
シモン芋エキスとシモン芋由来のスフィンゴ糖脂質、及びその製造方法 Download PDFInfo
- Publication number
- JP5150891B2 JP5150891B2 JP2005216813A JP2005216813A JP5150891B2 JP 5150891 B2 JP5150891 B2 JP 5150891B2 JP 2005216813 A JP2005216813 A JP 2005216813A JP 2005216813 A JP2005216813 A JP 2005216813A JP 5150891 B2 JP5150891 B2 JP 5150891B2
- Authority
- JP
- Japan
- Prior art keywords
- simon
- cocoon
- derived
- simmon
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000284 extract Substances 0.000 title claims description 122
- 150000002339 glycosphingolipids Chemical class 0.000 title claims description 99
- 238000004519 manufacturing process Methods 0.000 title claims description 33
- 238000000034 method Methods 0.000 claims description 132
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 82
- 210000002569 neuron Anatomy 0.000 claims description 56
- 239000002798 polar solvent Substances 0.000 claims description 52
- 239000000243 solution Substances 0.000 claims description 47
- 238000001035 drying Methods 0.000 claims description 45
- 239000007788 liquid Substances 0.000 claims description 42
- 238000007654 immersion Methods 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- 230000008569 process Effects 0.000 claims description 26
- 238000006460 hydrolysis reaction Methods 0.000 claims description 19
- 230000007062 hydrolysis Effects 0.000 claims description 17
- 239000007787 solid Substances 0.000 claims description 17
- 239000012190 activator Substances 0.000 claims description 15
- 241000220223 Fragaria Species 0.000 claims description 9
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 9
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000012670 alkaline solution Substances 0.000 claims description 9
- 238000007598 dipping method Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 229930186217 Glycolipid Natural products 0.000 description 119
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 101
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 89
- 210000004027 cell Anatomy 0.000 description 68
- 230000000694 effects Effects 0.000 description 53
- 238000004809 thin layer chromatography Methods 0.000 description 36
- 241000196324 Embryophyta Species 0.000 description 25
- 241001465754 Metazoa Species 0.000 description 24
- 239000000126 substance Substances 0.000 description 24
- 150000002270 gangliosides Chemical class 0.000 description 21
- 238000011161 development Methods 0.000 description 20
- 230000018109 developmental process Effects 0.000 description 20
- 108010025020 Nerve Growth Factor Proteins 0.000 description 18
- 102000015336 Nerve Growth Factor Human genes 0.000 description 17
- 230000014511 neuron projection development Effects 0.000 description 17
- 244000061456 Solanum tuberosum Species 0.000 description 15
- 235000002595 Solanum tuberosum Nutrition 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 14
- 235000013402 health food Nutrition 0.000 description 14
- 210000003757 neuroblast Anatomy 0.000 description 14
- 238000013467 fragmentation Methods 0.000 description 13
- 238000006062 fragmentation reaction Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000020411 cell activation Effects 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 238000004108 freeze drying Methods 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 230000003213 activating effect Effects 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 11
- 235000018927 edible plant Nutrition 0.000 description 11
- -1 for example Substances 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 239000002994 raw material Substances 0.000 description 11
- 235000011511 Diospyros Nutrition 0.000 description 10
- 229930182558 Sterol Natural products 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 229930182470 glycoside Natural products 0.000 description 10
- 235000003702 sterols Nutrition 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- HOMYIYLRRDTKAA-UHFFFAOYSA-N 2-hydroxy-N-[3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]hexadecanamide Chemical compound CCCCCCCCCCCCCCC(O)C(=O)NC(C(O)C=CCCC=CCCCCCCCCC)COC1OC(CO)C(O)C(O)C1O HOMYIYLRRDTKAA-UHFFFAOYSA-N 0.000 description 9
- 244000236655 Diospyros kaki Species 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 210000005036 nerve Anatomy 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 210000004748 cultured cell Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 102000012440 Acetylcholinesterase Human genes 0.000 description 7
- 108010022752 Acetylcholinesterase Proteins 0.000 description 7
- 241000519695 Ilex integra Species 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 7
- 229940022698 acetylcholinesterase Drugs 0.000 description 7
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 7
- 125000003900 glycosphingolipid group Chemical group 0.000 description 7
- 239000011259 mixed solution Substances 0.000 description 7
- 210000002241 neurite Anatomy 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 240000007594 Oryza sativa Species 0.000 description 6
- 235000007164 Oryza sativa Nutrition 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 6
- 235000009566 rice Nutrition 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000002791 soaking Methods 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 241000020719 Satsuma Species 0.000 description 5
- VELGMVLNORPMAO-HMWOVMCASA-N beta-D-galactosyl-(1->3)-N-acetyl-beta-D-galactosaminyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-stearoylsphingosine Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 VELGMVLNORPMAO-HMWOVMCASA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 244000144972 livestock Species 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000012535 impurity Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 244000017020 Ipomoea batatas Species 0.000 description 3
- 235000002678 Ipomoea batatas Nutrition 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 3
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000006866 deterioration Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 229940027779 persimmon extract Drugs 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 150000003313 saccharo lipids Chemical class 0.000 description 3
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 125000002421 ganglioside group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011899 heat drying method Methods 0.000 description 2
- 150000002402 hexoses Chemical class 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 150000003019 phosphosphingolipids Chemical class 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 238000000859 sublimation Methods 0.000 description 2
- 230000008022 sublimation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000207782 Convolvulaceae Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000723267 Diospyros Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000985282 Symbion Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000003352 adrenal gland pheochromocytoma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000008555 neuronal activation Effects 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/10—Production of fats or fatty oils from raw materials by extracting
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Description
本工程の「乾燥」は、前記乾燥工程(S0201)の乾燥とは水分以外の液体も減じる点と乾燥させる対象が異なる。すなわち、本工程の「乾燥」では、シモン芋エキス中に溶解している糖脂質を固体として取りだすために、シモン芋エキス中に存在する水分、又は糖脂質の抽出に使用した極性溶媒等の液体を除去することを言う。ただし、液体の完全除去は必要ではなく、固体状になるか、又は含液体率(シモン芋エキスの完全乾燥重量に対する当該液体の割合)が20%以下となればよい。
<シモン芋由来の糖脂質を含有するシモン芋エキス製造方法>
前記実施形態3によるシモン芋由来の糖脂質を含有するシモン芋エキス製造方法に関する実施例を以下で説明する。
前記実施形態5によるシモン芋由来のスフィンゴ糖脂質製造方法に関する実施例を以下で説明する。
実施例1で得られるシモン芋エキス中にシモン芋由来の糖脂質が含まれること、及び実施例2で得られた産物にシモン芋由来のスフィンゴ糖脂質が高濃度で含まれることを確認するためにTLCによって分析した。
シモン芋が一般的に知られる食用植物よりもスフィンゴ糖脂質を多量に含有することを確認するために、シモン芋と他の食用植物におけるスフィンゴ糖脂質の含有量を比較検証した。
シモン芋由来の糖脂質がヒト神経芽細胞を活性化できるかについての検証を行った。実験方法と結果を以下で説明する。なお、本実施例以降で培養細胞に用いる器具や試薬、水等は特に断りのない限りは、原則として全て滅菌処理済みのものを使用し、操作はクリーンベンチ、又は無菌室にて行うことを前提とする。
シモン芋由来の糖脂質がラット副腎褐色細胞腫細胞PC12を神経細胞に分化誘導し、神経突起様突起の伸長を活性するか、また細胞増殖活性を有するかの評価を行った。詳細な実験方法と結果を以下で説明する。
実施例5、又は6においてシモン芋由来の糖脂質で見られた神経突起若しくは神経突起様突起の伸長活性が、糖脂質の中のスフィンゴ糖脂質によるものかを確認した。また、実施例4で検出されたシモン芋特有のスフィンゴ糖脂質(植物性GM1近似物質)が特に神経突起の伸長活性を有するかを確認した。
1202:無添加2日目のSK−N−SH細胞
1203:NGF添加後2日目のSK−N−SH細胞
1204:水抽出シモン芋エキス添加後1日目のSK−N−SH細胞
1205:水抽出シモン芋エキス添加後2日目のSK−N−SH細胞
1206:エタノール抽出シモン芋エキス添加後1日目のSK−N−SH細胞
1207:エタノール抽出シモン芋エキス添加後2日目のSK−N−SH細胞
1208:除スフィンゴ糖脂質分画添加後1日目のSK−N−SH細胞
1209:除スフィンゴ糖脂質分画添加後2日目のSK−N−SH細胞
1210:スフィンゴ糖脂質分画添加後1日目のSK−N−SH細胞
1211:スフィンゴ糖脂質分画添加後2日目のSK−N−SH細胞
1212:精製した植物性GM1近似物質添加後1日目のSK−N−SH細胞
1213:精製した植物性GM1近似物質添加後2日目のSK−N−SH細胞
1214:水抽出シモン芋エキスのTLC展開図
1215:エタノール抽出シモン芋エキスのTLC展開図
1216:除スフィンゴ糖脂質分画のTLC展開図
1217:スフィンゴ糖脂質分画のTLC展開図
1218:精製した植物性GM1近似物質のTLC展開図
A:グリコシルセラミド、ステロール配糖体、及びグリセロ糖脂質群
B:除去しきれなかったAの各物質
C:スフィンゴ糖脂質群
D:植物性GM1近似物質
Claims (2)
- シモン芋を極性溶媒中に浸たす浸漬工程と、
前記浸漬工程で得られる浸漬液を濃縮する濃縮工程と、からなり、
前記濃縮工程は濃縮することにより得られる液状シモン芋エキスを乾燥させて固体状シモン芋エキスを得る工程である
シモン芋エキス製造方法により得られるシモン芋エキスに
アルカリ溶液を加えてグリセロ糖脂質を加水分解する加水分解工程と、
前記加水分解工程で得られた加水分解溶液にクロロホルムと水を加えて混合した後、クロロホルム溶液を取得するクロロホルム溶液取得工程と、
前記クロロホルム溶液取得工程で取得されたクロロホルム溶液からクロロホルムを除去してシモン芋由来のスフィンゴ糖脂質を取得するスフィンゴ糖脂質取得工程と、
からなるシモン芋由来のスフィンゴ糖脂質製造方法。 - 請求項1に記載のスフィンゴ糖脂質製造方法により得られるスフィンゴ糖脂質を有効成分として含む神経細胞を活性化する神経細胞活性化剤。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005216813A JP5150891B2 (ja) | 2005-07-27 | 2005-07-27 | シモン芋エキスとシモン芋由来のスフィンゴ糖脂質、及びその製造方法 |
PCT/JP2006/314787 WO2007013522A1 (ja) | 2005-07-27 | 2006-07-26 | シモン芋エキスとシモン芋由来のスフィンゴ糖脂質、及びその製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005216813A JP5150891B2 (ja) | 2005-07-27 | 2005-07-27 | シモン芋エキスとシモン芋由来のスフィンゴ糖脂質、及びその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007031338A JP2007031338A (ja) | 2007-02-08 |
JP5150891B2 true JP5150891B2 (ja) | 2013-02-27 |
Family
ID=37683413
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005216813A Active JP5150891B2 (ja) | 2005-07-27 | 2005-07-27 | シモン芋エキスとシモン芋由来のスフィンゴ糖脂質、及びその製造方法 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5150891B2 (ja) |
WO (1) | WO2007013522A1 (ja) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63283552A (ja) * | 1987-05-15 | 1988-11-21 | Iino Akira | ブラジル原産白甘薯を主体とした健康食品 |
JP2001261542A (ja) * | 2000-03-17 | 2001-09-26 | Pola Chem Ind Inc | マッサージ化粧料 |
JP4753476B2 (ja) * | 2001-01-30 | 2011-08-24 | ユニチカ株式会社 | スフィンゴ糖脂質を含有する化粧品 |
-
2005
- 2005-07-27 JP JP2005216813A patent/JP5150891B2/ja active Active
-
2006
- 2006-07-26 WO PCT/JP2006/314787 patent/WO2007013522A1/ja active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2007013522A1 (ja) | 2007-02-01 |
JP2007031338A (ja) | 2007-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102287247B1 (ko) | 반려동물 관절 영양제 조성물 | |
JP6876724B2 (ja) | 塩生植物由来の機能性が強化した脱塩栄養組成物とその製造方法 | |
KR101352282B1 (ko) | 시알산 함량이 증가된 녹용 추출물의 제조 방법 | |
JP2017171747A (ja) | 日向夏みかん由来のアラビノガラクタン | |
KR101413328B1 (ko) | 미역귀를 이용한 미백 기능성 화장품 원료추출방법 및 이를 이용한 미백 기능성 화장품 | |
JP2013039087A (ja) | プロテオグリカンを含有してなる飲料水及びその製造方法 | |
JP5150891B2 (ja) | シモン芋エキスとシモン芋由来のスフィンゴ糖脂質、及びその製造方法 | |
KR101783672B1 (ko) | 유아 분변에서 분리한 균주 및 이를 이용한 항산화 및 면역강화 기능을 갖는 발효유의 제조방법 | |
KR101344055B1 (ko) | 더덕 추출물의 발효물을 유효성분으로 함유하는 간기능 개선용 조성물 | |
KR20090127785A (ko) | 다시마 주요성분을 적절히 분리 추출, 농축, 전부 활용,오염을 유발하지 않는 다시마 완전 처리공정 | |
JP7464931B2 (ja) | 新規ムチン型糖タンパク質およびその用途 | |
JP2006347951A (ja) | 神経細胞活性化作用を有するトリペプチド、それからなる食品製剤、化粧品及び抗認知症剤 | |
TWI726184B (zh) | 褐藻多醣及其製造方法暨應用 | |
JP5537924B2 (ja) | シルバースキン抽出物を用いたヒアルロニダーゼ阻害剤およびその製造方法 | |
RU2351166C1 (ru) | Способ получения инулина из одуванчика лекарственного | |
WO2021256544A1 (ja) | 全果りんご及び・又はリンゴ搾汁残渣からセラミド含有物又はセラミドを抽出する方法及びそのセラミドを含む組成物 | |
JP2008274106A (ja) | スフィンゴ脂質含有組成物の製造方法 | |
JP2010057483A (ja) | 内臓知覚過敏改善食品 | |
JP5577019B2 (ja) | 経口投与組成物 | |
JPWO2007069733A1 (ja) | アルカリ水溶液を用いたセラミド関連物質の製造方法とその装置 | |
KR101873836B1 (ko) | 항고지혈증 및 항당뇨 활성을 갖는 그물말속 조류 추출물 및 이를 이용한 조성물 | |
JP5744126B2 (ja) | スフィンゴ脂質含有組成物の製造方法 | |
RU2449803C1 (ru) | Способ получения пектоинулина из клубней топинамбура | |
JP6606636B2 (ja) | 細胞膜安定化作用を呈するベツリン誘導体及びその製造方法 | |
JP2020110160A (ja) | コレステロール吸収阻害剤及びこれを含む食品並びに医薬品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080709 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080902 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20080904 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110830 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120131 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20120209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120210 |
|
AA92 | Notification that decision to refuse application was cancelled |
Free format text: JAPANESE INTERMEDIATE CODE: A971092 Effective date: 20120424 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120618 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20120809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120813 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120914 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121004 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121108 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151214 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5150891 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151214 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |